Food and Drug Administration

 

Peripheral and Central Nervous System Advisory Committee

 

April 28, 1999

 

Slides

 

Disclaimer

 

The statements contained in this document(s) are those of the product’s sponsor, not FDA, and FDA does not necessarily agree with the sponsor’s statemtns.  FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

 

 

Aggrenox™, Manfred Haehl, M.D.

 Boehringer Ingelheim Pharmaceuticals, Inc.

[HTML]    [PPT]

 

Clinical Overview, Gregory W. Albers, M.D.

Stanford University

[HTML]    [PPT]

 

Aggrenox™ Development Rationale, Thomas Müller, M.D., Ph.D.

Blood Transfusion Center of the German Red Cross

[HTML]    [PPT]

 

Clinical Trial Efficacy, James Street, Ph.D.

Boehringer Ingelheim Pharmaceuticals, Inc.

[HTML]    [PPT]

 

Aggrenox™ Safety, Kenneth Rakowski, M.D.

Boehringer Ingelheim Pharmaceuticals, Inc.

[HTML]    [PPT]

 

Conclusion, Manfred Haehl, M.D.

Boehringer Ingelheim Pharmaceuticals, Inc.

[HTML]    [PPT]